Onconetix, Inc.

Stage 4 · Declining · week 46

As of Oct 22, 2026, Onconetix is in Stage 4, the downtrend phase, now in week 46 (since Nov 24, 2025). It closed at $0.41, 99.8% below its 52-week high and below its 200-day average, which is falling.

$0.41

-6.44% today

$2.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ONCO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 41w

S4 62w

S4 48w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 41w → S1 9w → S4 62w → S1 4w → S4 48w current

Total tracked: 166 weeks across 6 stage runs.

ONCO among Biotechnology551st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…551	ONCOOnconetix, Inc.	Stage 4 · wk 46	2	−55.3%

vs 52W High

-99.8%

$0.41 lo$189.50 hi

99.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 46

1w13w26w

Week 46, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-97.5%

200 DMA: $16.36 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.14x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-55.3%

-50.4%

-93.9%

YTD

-99.5%

-99.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 46 · Vol 0.14x

2026-10-21S4

Wk 46 · Vol 0.19x

2026-10-20S4

Wk 46 · Vol 0.09x

2026-10-19S4

Wk 46 · Vol 0.10x

2026-10-16S4

Wk 45 · Vol 0.18x

2026-10-15S4

Wk 45 · Vol 0.04x

2026-10-14S4

Wk 45 · Vol 0.07x

2026-10-13S4

Wk 45 · Vol 0.09x

2026-10-12S4

Wk 45 · Vol 0.22x

2026-10-09S4

Wk 44 · Vol 0.30x

2026-10-08S4

Wk 44 · Vol 17.42x

2026-10-07S4

Wk 44 · Vol 0.23x

Moving averages & range

50 DMA

$0.69

200 DMA

$16.36

52W High

$189.50

52W Low

$0.41

5D Low

$0.41

Resistance levels (recent highs)

20d High

$1.11

60d High

$1.11

120d High

$6.47

250d High

$189.50

Next resistance

+172.7%

to 20d High

P/E (TTM)

0.0

Forward -0.5

ROE

-105.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.1

Onconetix: quick answers

What stage is Onconetix in?

As of Oct 22, 2026, Onconetix (ONCO) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 24, 2025 and is in week 46. What the four stages mean

Is Onconetix in an uptrend?

No. Onconetix is in a Stage 4 downtrend. It trades 97.5% below its 200-day average, which is falling.

How far is Onconetix from its 52-week high?

Onconetix closed at $0.41 on Oct 22, 2026, 99.8% below its 52-week high of $189.50. Its 52-week low is $0.41.

How has Onconetix performed over the past year?

As of Oct 22, 2026, Onconetix is down 99.8% over the past year and down 99.5% so far in 2026.

Which sector and industry is Onconetix in?

Onconetix is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.